AUTOLOGOUS BMT WITH EX VIVO PURGING WITH 4-HC FOR PATIENTS WTIH ANLL

针对 ANLL 患者使用 4-HC 进行体外净化的自体 BMT

• 批准号: 3766607
• 负责人: JOSEPH ANTIN
• 金额: --
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766607
• 关键词: acute nonlymphocytic leukemia; antineoplastics; autologous transplantation; bone marrow purging; bone marrow transplantation; busulfan; clinical trials; combination cancer therapy; cyclophosphamide; drug adverse effect; human morbidity; human subject; human therapy evaluation; neoplasm /cancer chemotherapy

This is a Phase II trial of the marrow-purging reagent 4-hydroperoxycyclophosphamide, a cyclophosphamide congener that is activated upon contact with water. Patients are conditioned with busulfan and cyclophosphamide and receive autologous marrow that has been purged with 4-HC. We are examining rate of engraftment, disease-free survival and toxicity.

这是骨髓净化试剂的 II 期试验 4-氢过氧环磷酰胺，一种环磷酰胺同系物， 与水接触后被激活。患者接受白消安调节 和环磷酰胺并接受已净化的自体骨髓 与 4-HC。 我们正在检查植入率、无病生存率 和毒性。